Scientists test drug combo to boost Cancer-Killing transplant
NCT ID NCT07044544
Summary
This early-stage trial is testing if adding two anti-cancer drugs, decitabine and venetoclax, to a standard stem cell transplant procedure is safe for adults with high-risk blood cancers like acute myeloid leukemia (AML). The main goal is to find the safest dose and see if this combination helps control the cancer better after transplant. About 20 participants will be enrolled to carefully monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.